Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh by Khatun, Sabera et al.
Safety and Immunogenicity Proﬁle of Human Papillomavirus-16/18
AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled
Trial in Healthy Adolescent Girls of Bangladesh
Sabera Khatun1, Syed Md Akram Hussain2,*, Sameena Chowdhury3, Jannatul Ferdous1, Fawzia Hossain1,
Sultana Razia Begum1, Munira Jahan4, Shahina Tabassum4, Shahla Khatun5 and ABM Fazlul Karim6
1Gynae-Oncology Division, Department of Obstetrics and Gynecology, Bangabandhu Sheikh Mujib Medical
University,
2Department of Oncology, Bangabandhu Sheikh Mujib Medical University,
3Central Hospital,
4Department of Virology, Bangabandhu Sheikh Mujib Medical University,
5Department of Gynecology,
Bangladesh Medical College and
6Japan–Bangladesh Friendship Hospital, Dhaka, Bangladesh
*For reprints and all correspondence: Syed Md Akram Hussain, Department of Oncology, BSMMU,
Dhaka 1000, Bangladesh. E-mail: syedmdakram@gmail.com
Received June 9, 2011; accepted November 4, 2011
Aim: Bangladesh has the highest level of incidence and mortality rates due to cervical cancer
among women. The prevalence of cervical cancer in Bangladeshi women is 25–30/100 000.
Human papillomavirus is an important cause of cervical cancer. The study was conducted to
assess the immunogenicity and safety proﬁle of human papillomavirus-16/18 AS04-adju-
vanted cervical cancer vaccines in healthy Bangladeshi girls aged 9–13 years.
Procedure: This was a randomized (3:1) controlled trial with two parallel groups, the vaccine
and control groups, that included 67 participants in Bangladesh. Subjects were given
GlaxoSmithKline human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine (and
controls no vaccine) at the ﬁrst day of vaccination (Day 0), at 1- and 6-month schedule and
followed up until 7 months. Blood samples were taken for human papillomavirus antibody at
enrollment and 1 month post-schedule at Month 7 from both subjects and controls. Safety
data were gathered throughout the study period.
Results: Fifty subjects received vaccine at Day 0, 1 month and 6 months. All subjects were
initially sero-negative in the vaccine group, and developed sero-conversion for human
papillomavirus-16 and -18 antibodies except for one at Month 7. Seventeen controls did
not receive vaccine. Clients were followed up for serious medically important events
and blood samples were taken for human papillomavirus antibody detection at Day 0 and
Month 7. Sero-conversion was found in 97.5% of subjects and no sero-conversion was found
in the controls. Bivalent human papillomavirus vaccine was generally well tolerated, with no
vaccine-related serious adverse experiences.
Conclusions: The human papillomavirus-16/18 AS04-adjuvanted vaccine was generally well
tolerated and highly immunogenic when administered to young adolescent females and could
be a promising tool for the prevention and control of cervical cancer in Bangladesh.
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Almost half a million women develop cervical cancer and
.288000 women die each year worldwide, the disease dis-
proportionately affecting the poorest, most vulnerable
women. At least 80% of cervical cancer deaths occur in
developing countries, with most occurring in the poorest
regions—South Asia, Sub-Saharan Africa and parts of Latin
America, where cervical cancer accounts for 15% of all
cancer deaths but which have only 5% of the world’s cancer
resources (1).
Health-care providers in developing countries regularly
see women with advanced, incurable cervical cancer, and
around 28.9% incidence and 17.9% mortality of all cancer
cases have been reported in Bangladesh (2). An Indian study
showed that nearly 70% of cervical cancer patients present at
Stages III and IV of the disease. Around 20% of women
who develop cervical cancer die within the ﬁrst year of diag-
nosis and the 5-year relative survival rate is 50% (3). At this
late stage, there is little to do to save women’s lives. Even
drugs designed to ease cancer pain often are unavailable.
Yet cervical cancer can be readily prevented, even in women
at high risk for the disease, through screening and treatment
using relatively simple technologies. When pre-cancerous
changes in cervical tissue are found and the abnormal tissue
is successfully treated, a woman will not develop cancer.
Human papillomavirus (HPV) infection is one of the most
common sexually transmitted diseases worldwide. Up to
70% of sexually active women worldwide will become
infected with HPV during their lifetime (4). HPV, particular-
ly the two strains HPV-16 and -18, accounts for most cer-
vical cancer cases. Genital HPV is usually transmitted via
the vaginal and anal route. Infection is common within a few
years of onset of intercourse. The prevalence of HPV infec-
tion among women in Bangladesh has been reported to be
4.1% (5). Importantly, the rate of HPV infection in women
younger than 25 years was roughly double that in women
older than 25 years of age in the same city in a recent study
(33%) (6). Moreover, HPV prevalence has been reported to
be 38% in a cohort of sexually active female college students
in Busan (7).The sexual transmission of HPV is an important
factor to consider for vaccination strategies, including the
optimal age of vaccination. Persistent HPV infection is asso-
ciated with the development of cervical and other ano-
genital cancers (8–10). In a study regarding HPV genotype
distribution in invasive cervical carcinoma, it was found that
HPV-16 and -18 were the major type in all continents (11).
For example, .50% of college-age women acquired an
HPV infection within 4 years of ﬁrst intercourse (12).
There is a huge discrepancy in incidence between devel-
oped and developing countries largely due to the availability
of screening and treatment facilities in industrialized coun-
tries. Although widespread and organized screening pro-
grams using Papanicolaou (Pap) testing may reduce the
mortality associated with cervical cancer worldwide, screen-
ing does not prevent HPV infection or the development of
pre-cancerous lesions that may require treatment such as cer-
vical intraepithelial neoplasia cases or carcinoma in situ.
Therefore, a mechanism for primary prevention of HPV in-
fection is desirable.
A vaccine to prevent oncogenic HPV infection, or prema-
lignant cervical lesions from progressing to cancer, would
clearly offer a cost-effective long-term strategy to reduce the
cervical cancer burden, particularly for developing countries
where effective screening programs are not available.
Recombinant DNA technology is being used to produce vac-
cines against HPV, and both prophylactic and therapeutic
vaccines are in use. Virus-like particles (VLPs) as recombin-
ant L1 capsid protein from HPV contain no viral DNA and
are therefore non-infectious and stimulate the production of
antibodies that bind and neutralize the infectious virus. Live
recombinant vectors such as recombinant vaccinia viruses,
engineered to express genes from HPV-16 and -18, the most
common viruses associated with cervical cancer, have been
tested in therapeutic settings. The vaccine prevented 100%
of high-grade cervical pre-cancers and non-invasive cervical
cancers that were associated with HPV-16 and -18 (13).
Given the long record of prophylactic viral vaccines as a
cost-effective approach to prevent infection or modify
disease, an effective vaccine against oncogenic types of
HPV could have a tremendous impact on the global cervical
cancer burden. Therefore, vaccination against HPV-16 and
-18 will beneﬁt the women of poor countries such as
Bangladesh, who have limited access to testing and
treatment.
In this study, we assessed the immunogenicity and safety
proﬁle of HPV-16/18 AS04-adjuvanted cervical cancer
vaccine in adolescent girls aged between 9 and 13 years en-
rolled from Bangladesh in a randomized, controlled trial and
compared the occurrence of serious adverse events (SAEs)
between the two groups. HPV-16 and -18 antibody titers
were assessed by enzyme-linked immunosorbent assay
post-vaccination.
PATIENTS AND METHODS
VACCINE AND CONTROL GROUPS
This randomized (3:1) controlled clinical trial with two par-
allel groups, the vaccine and control groups, included 67 par-
ticipants from Bangabandhu Sheikh Mujib Medical
University and from two private hospitals in Bangladesh.
The study was conducted from March 2008 to July 2009.
GlaxoSmithKline’s HPV-16/18 AS04-adjuvanted cervical
cancer vaccine was given ﬁrst day of vaccination (Day 0), at
the 1- and 6-month schedule and followed up until Month
7. Controls were not given any vaccine. Serum samples were
drawn at pre-vaccination and at Month 7 from both groups.
Safety data were collected throughout the study. Main
outcome measures were HPV-16/18 sero-conversion rates at
Month 7 (in HPV-16/18 recipients) and safety.
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unmarried and sexually unexposed girls aged 9–13 years.
Exclusion criteria were febrile illness at the time of vaccin-
ation, enrollment in another study with investigational
agents, history of allergy to vaccine compounds (including
aluminum, yeast), thrombo-cytopenia, history of another vac-
cination within 14 days of enrollment (previous 21 days for
live vaccine), transfusion of blood or blood-derived products
within 6 months preceding injection, immuno-suppression,
diarrhea, vomiting and bleeding disorders. The vaccinated
girls agreed to have no sexual exposure during the study
period. As the girls were unmarried and sexually unexposed
before enrollment into the study, Pap test, HPV identiﬁcation
and visual inspection with acetic acid were not done.
ETHICS
The protocol and materials were approved by the ethical
review committee of Bangladesh Medical Research Council
and Bangabandhu Sheikh Mujib Medical University. Written
informed consent was obtained from all participants or their
parents or legal guardian or both after informing about the
vaccination procedure.
RANDOMIZATION
We randomly assigned participants in a 3:1 ratio to either
the vaccination group or the control group.
IMMUNOGENICITY ASSESSMENTS
Cervarix
TM is a bivalent HPV-16/18 LI VLP vaccine devel-
oped by GlaxoSmithKline (Cervarix, GlaxoSmithKline
Biologicals, Rixensart, Belgium). In this preparation, the L1
protein of each HPV type is expressed via a recombinant
baculo virus vector. The VLPs of each HPV type are pro-
duced separately and consist of puriﬁed L1 VLPs of
HPV-16/18 at 20/20-g per dose formulated on AS04 adju-
vant comprising 500 gm of aluminum hydroxide and 50 gm
of 3-deacylated monopods phage lipid A.
Each subject received three doses of vaccine (0.5 ml) at
Day 0, 1 month and 6 months. Blood samples were obtained
from all subjects before vaccination, at the ﬁrst day of vac-
cination (Day 0) and at Month 7. HPV IgG antibodies to
HPV-16/18 were detected by capture enzyme-linked im-
munosorbent assay with a commercially available kit. A
cut-off value was calculated from the mean optical density
(OD) of the negative control at 450 nm. A cut-off value
permits us to transform the OD values detected in positive
or negative results due to the presence or absence of
anti-HPV IgG. Samples with an OD of 450 nm lower than
the cut-off value were considered as non-reactive for IgG
anti-HPV. Samples with an OD of 450 nm higher than the
cut-off value were considered as positive for IgG anti-HPV.
The control group did not receive any vaccine.
Sero-conversion/sero-positivity rates for anti-HPV-16 and
anti-HPV-18 antibodies were calculated with a 95% conﬁ-
dence interval (CI).
Safety proﬁle assessments of local symptoms (pain,
redness and swelling at the injection site) and general symp-
toms (fever, headache, fatigue, gastrointestinal symptoms
that included nausea, vomiting, diarrhea and/or abdominal
pain, arthralgia, myalgia, rash and urticaria) were recorded
for ﬁve consecutive days after each dose. The intensity of
each symptom was graded on a non-quantiﬁable scale from
mild, moderate and severe based on the extent of discomfort
that subjects experienced. Unwanted events were followed
for 14 days after each vaccination. SAE was classiﬁed by the
Medical Dictionary for Regulatory Activities (14).
STATISTICAL ANALYSIS
Evaluation of the vaccine-induced serum anti-HPV-16 and
anti-HPV-18 responses following administration of a three-
dose regimen of bivalent HPV vaccine in female subjects
aged 9–13 years in Bangladesh was done. Evaluation of the
vaccine-induced serum anti-HPV responses following admin-
istration of three doses was done by the exact binomial test
and 95% CIs were calculated. Risk differences in the per-
centage of subjects with one or more adverse experiences
were estimated and their 95% CIs were provided.
A three-dose regimen of bivalent HPV vaccine is general-
ly well tolerated in female subjects 9–13 aged years in
Bangladesh. Speciﬁc adverse experiences, the incidence of
injection-site adverse experiences and systemic clinical
adverse experiences occurring on Days 1–15 of the post-
vaccination period, were tabulated for the vaccination group.
Risk differences in the percentage of subjects with one or
more adverse experiences were estimated and their 95% two-
sided CIs were provided.
RESULTS
SOCIO-DEMOGRAPHIC CHARACTERISTICS
A total of 67 healthy subjects consented to participate and
were enrolled and randomized (Fig. 1). Of these subjects, 50
received vaccine, and among these 50 subjects, 49 (98%)
received all of the three-dose planned vaccination. Only 17
developed some adverse effects and were followed up for
any medically important disease. Forty (80%) attended all
visits and completed the study up to 7 months. Dose 3 of
vaccination of one subject was done at a later date, as the re-
cipient was absent. One subject from the vaccine group
received only two vaccines because of shifting from Dhaka
to a peripheral district. Demographic data are presented in
Table 1. It was found that the mean age of vaccinated girls
was 11.1 years with SD þ 1.4 (range: 9–13 years) and the
mean age of the control group was 12.9 þ 206.The mean
age of menarche was 11.2 in the vaccinated group and 12.5
in the control group. All the adolescent girls (100%) in both
groups were unmarried.
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control group were illiterate. Twenty-six percent of the vac-
cinated group and 11.8% of the control group had a primary
level of education (1–5 years of schooling). Fifty-six
percent of the vaccinated group and 41.2% of the control
group had a secondary level of education (6–10 years of
schooling; Fig. 2).
IMMUNOGENICITY
Vaccine-induced immune responses were assessed in both
the vaccine/subject and control groups (Table 1). Among 49
vaccinated subjects, 40 were available for detection of anti-
body to HPV. Among them, vaccine-induced sero-
conversion was found in all subjects except 1. Nine subjects
were not available for antibody detection at 7 months.
Inoculation of Dose 3 of the sero-non-converted subject was
done after 4 days due to absence.
Vaccine-induced antibody titer was high. Sero-conversion
was not found among the control group. Two girls from
the control group did not give blood samples for antibody
detection (Table 1).
SAFETY PROFILE
In general, the bivalent HPV vaccine was well tolerated with
no reports of serious vaccine-related adverse experiences
between enrollment and Month 7. Adverse effect after differ-
ent doses of vaccine is shown in Figs 3–6.
Among the vaccinated group, about 80% after the ﬁrst
dose, 88% after the second dose and 90% after the third
dose of vaccination had at least one adverse experience.
Among the vaccinated group, 20% after the ﬁrst dose, 12%
after the second dose and 10% after the third dose had no
medical illness (Fig. 3).
Fever and injection-site-related adverse reaction were seen
in those who had received vaccine (44 and 50%, respective-
ly) after the ﬁrst dose of vaccination, though most were mild
in intensity. Injection-site pain was the most common
vaccine-related adverse experience seen in those who had
received vaccines (50, 72 and 50% after the ﬁrst, second and
third dose of vaccination, respectively). Vomiting was
Table 1. Summary of anti-HPV antibody after vaccination
Subject Control P-value
N (%) 95% CI N (%) 95% CI
Anti-HPV positive 39/40 (97.5) 86.8–99.9 0/15 (0.0) 0.0–21.8 0.001
Figure 2. Distribution of level of education of vaccinated and control
groups.
Figure 1. Age distribution of vaccine and control groups.
Figure 3. Percentage of one or more adverse effects by doses.
Figure 4. Percentage of adverse effect in subjects after ﬁrst dose.
Figure 5. Percentage of adverse effect in subjects after second dose.
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after the second dose and 16 subjects after the third dose of
vaccination (Figs 4–6).
No severe adverse experience was observed. Though
vaccine related some adverse effects were observed in the
vaccinated group but these are statistically not signiﬁcant.
Fever and injection-site adverse reaction was subsided by
taking acetaminophen 500 mg three times daily for 1 or 2
days.
DISCUSSION
A range of studies conducted globally with efﬁcacy trials
with bivalent and quadrivalent HPV vaccine demonstrated
its high efﬁcacy and immunogenicity. Nevertheless, concerns
exist regarding the effect of racial or ethnic difference on im-
munogenicity and safety of the vaccine. A recent report indi-
cates that racial differences may affect the neutralizing
antibody response to an investigational HIV vaccine (15).
The present study showed high immunogenicity of the
HPV-16/18 AS04-adjuvanted cervical cancer vaccine among
Bangladeshi adolescent girls. We found that all initially sero-
negative subjects in the vaccine group sero-converted for
both antibodies at the 7-month post-third dose, while the ini-
tially sero-negative control recipients had no change from
the pre-vaccination titers in anti-HPV-16 and anti-HPV-18.
Therefore, the bivalent HPV VLP vaccine is generally tol-
erable and highly immunogenic in Bangladeshi girls aged
9–13 years. This vaccine can possibly protect women who
have not been previously sexually exposed. The AS04 adju-
vant was found to be key in inducing and maintaining an
enhanced immune response (16) .T h ei n d u c t i o no fh i g hi m -
munogenicity by the AS04-adjuvanted vaccine has also been
conﬁrmed in a recent study (17).
The clinical importance of the data presented herein stems
from their applicability to the South-East Asian population
as a whole, where the incidence of cervical cancer is still
high despite the presence of cervical cancer screening pro-
grams. Bangladesh is a developing country and HPV infec-
tion remains a high risk for cervical cancer. The
age-adjusted rate of cervical cancer in Busan was reported to
be 21.8 cases per 100000 women, a rate higher than most
Western countries (18). In Bangladesh, though we have no
population-based cancer statistics, different hospital statistics
show that the rate of cervical cancer is 21.5% among all ma-
lignancies of women, a rate higher than any developing
country (19). However, according to Globocan (2), it is
higher, around 28.9% incidence and 17.9% mortality of all
cancer cases in Bangladesh. Therefore, due to lack of access
to appropriate screening facilities, there is an obvious public
health need to discover various approaches for preventing
cervical cancer. Vaccination is one of the approaches and
has the potential to play a crucial role in the prevention of
cervical cancer in Bangladesh (20,21).
Safety results in this study showed no signiﬁcant occur-
rence of adverse events in vaccine recipients, which is in
line with the data from large previous studies conducted glo-
bally (22,23). The solicited general symptoms occurred in
the vaccine group. Despite local injection site reactions
being reported at a higher frequency in the vaccine group,
there was similar conformity to the three-dose vaccination
schedule and follow-up 1 month post-third dose, as has also
been observed in other studies (22,24).
While the current study had a mean age of 11.1 years, the
mean age of women enrolled in the prior study from the
USA, Brazil and Europe was 20.0 years. Age was directly
related to HPV antibody response seen in a combined ana-
lysis of data from two large pivotal studies for the quadriva-
lent HPV vaccine conducted internationally (FUTURE I and
FUTURE II) (25,26). In combined data from these two
trials, subjects aged 9–15 years had a signiﬁcantly higher
antibody response as measured by geometric mean titer
against all vaccine-related HPV types when compared with
chosen subjects who were 16–26 years of age (27).
In Bangladesh, opportunistic screening sometimes prac-
tised for cervical cancer may be helpful in increasing aware-
ness of the disease. Nevertheless, it does not seem to have
made any signiﬁcant transformation on the mortality and
morbidity burden of the disease (28). Therefore, due to a
higher cervical cancer burden in Bangladesh and a deﬁcient
planned mass screening program for early detection, an ef-
fective prophylactic HPV vaccination program combined
with effective screening could facilitate the control and pre-
vention of cervical cancer in Bangladesh (29).
CONCLUSION
Among women aged 9–13 years not previously infected
with vaccine-type HPV strains, prophylactic HPV-16/18
AS04-adjuvanted vaccine appears to be highly immunogen-
ic, safe and generally well tolerated in adolescent girls from
Bangladesh. Immunization of girls against oncogenic HPV
before sexual debut could be a potential tool for the preven-
tion and control of cervical cancer in Bangladesh.
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